

ALOPECIA SNIPPETS

apex
SKINNOVA

How common is alopecia in India?

North India¹

Female pattern
hair loss
22%

Telogen
effluvium
62%

East India²

Alopecia areata
3%-43%

West India³

Alopecia areata
52.1%

South India^{4,5}

Male pattern hair loss
50.4% - 60.3% | Alopecia areata
37.9%
Telogen effluvium
8.8%

2022 brings new ray of hope for alopecia patients


Current conventional therapies for alopecia do not provide substantial improvement for many patients and have unacceptable adverse effects. This underscores the pressing need for approved therapies providing satisfying, long-term results. In this endeavor, researchers continue to explore new horizons, with a focus on developing more effective treatment options.

The ensuing paragraphs summarize findings from some recent trials that show the efficacy of two common arthritis drugs in hair regrowth, thus showing a new ray of hope for alopecia patients.

A common arthritis drug receives FDA approval for alopecia areata

- The FDA has approved baricitinib for adult patients with severe alopecia areata; the drug showed promising results in two phase 3 clinical trials.*
- The trials found that 1 in 3 patients with alopecia areata were able to regrow hair after treatment with baricitinib at 36 weeks (Figure 1).⁶

Figure 1: Efficacy of baricitinib in patients with alopecia areata




*BRAVE-AA1 and BRAVE-AA2 are the two phase 3 clinical trials

A fresh glimmer of hope for pediatric patients with alopecia

- A recent study published in the journal *Pediatric Dermatology* showed clinical efficacy of hair regrowth with oral tofacitinib in pediatric patients with alopecia areata
- In this study, approximately 73% patients experienced hair regrowth after taking oral tofacitinib (Figure 2).⁷

Figure 2: Efficacy of oral tofacitinib in children with alopecia areata



Emerging technologies in alopecia management

In recent years, we are seeing new developments in the treatment of alopecia; however, effective management remains challenging. At the same time, the need for efficacious products, rather than those with promises are much needed nowadays.

A wide range of active research projects, which centre on creating more efficient therapies, are aimed at meeting these demands. Patients, especially those who are dealing with severe hair loss, now have new hope because of this. The newly developed and upgraded technological innovations which stimulate the skin with gentle, low-frequency electric pulses to react to hair generation are available on the market.



HairBoom Air Helmet: A modern laser hair growth device

FDA has cleared a new laser hair growth device known as HairBoom Air. This latest model of the HairBoom series, HairBoom Air, uses a safe low-power laser therapy for scalp.⁸

Hair regrowth achieved with a wearable device powered by small body movements

Scientists have designed an unobtrusive, wearable electric stimulator that can fit under a baseball cap, captures energy from the natural movements of the head and converts it into electrical pulses to stimulate hair regrowth.⁹



AA-IGA: A new assessment scale for alopecia areata

The AA-IGA is a reliable five-grade investigator global assessment scale that can be used to analyze clinically significant treatment success for alopecia areata

It measures five clinically meaningful gradations of alopecia areata scalp-hair loss that reflect patients' and clinicians' perspectives and expectations of treatment success

As per the AA-IGA, hair regrowth resulting in $\leq 20\%$ scalp hair loss indicates treatment success for patients with $\geq 50\%$ scalp-hair loss.¹⁰

Abbreviation: AA-IGA; Alopecia Areata Investigator Global Assessment scale

References

1. Poonia K, Thami GP, Bhalla M, Jaiswal S, Sandhu J. NonScarring Diffuse Hair Loss in Women: a Clinico-Etiological Study from tertiary care center in North-West India. *J Cosmet Dermatol.* 2019;18(1):401-407.
2. Sharma R L, Mishra A, Zaman FA. A Clinicoepidemiological Study of Alopecia Areata with its Demographic Correlation in Anurban Hospital Setting in Odisha. *IJCMAAS.* 2017;3,137-140.
3. Jain S, Marfatia YS. Alopecia areata--pattern in industrial city of Baroda. *Indian J Dermatol Venereol Leprol.* 2003;69(2):81-2.
4. Shetty VM, Shanmukhappa AG, Nataraj HV, Aradhya SS. Hair Loss in Children: A Clinicoetiological Study from South India. *Int J Trichology.* 2021;13(6):17-25.
5. Varman PM, Paul CM, Rajan P, et al. Study on Hair Fall with Hair Related Problems among Males of Age 18-50 Years: Study on Chennai Based Population. *J Clin Diagn Res.* 2018;12,LC09-LC12.
6. King B, Ohyama M, Kwon O, et al. Two Phase 3 Trials of Baricitinib for Alopecia Areata. *N Engl J Med.* 2022; 386:1687-1699.
7. Kibbie J, Kines K, Norris D, Dunnick CA. Oral tofacitinib for the treatment of alopecia areata in pediatric patients. *Pediatr Dermatol.* 2022;39(1):31-34.
8. HairBoom Air Helmet FDA Cleared to Treat Hair Loss. Available at: <https://www.medgadget.com/2019/10/hairboom-air-fda-cleared-to-treat-hair-loss.html>. Accessed on: 17/06/2022.
9. Discreet Wearable for Hair Regrowth Using Body-Generated Electricity. Available at: <https://www.medgadget.com/2019/09/discreet-wearable-for-hair-regrowth-usingbody-generated-electricity.html>. Accessed on: 17/06/2022.
10. Wyrwich KW, Kitchen H, Knight S, et al. The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials. *Br J Dermatol.* 2020;183(4):702-709.

In Alopecia



In Premature Greying of Hair



In Androgenetic Alopecia



Scan this QR code
to see the video of
Dr. Koushik Lahiri on
alopecia awareness month

